Literature DB >> 25128670

Present status of quinoxaline motifs: excellent pathfinders in therapeutic medicine.

Olayinka Oyewale Ajani1.   

Abstract

Quinoxalines belong to a class of excellent heterocyclic scaffolds owing to their wide biological properties and diverse therapeutic applications in medicinal research. They are complementary in shapes and charges to numerous biomolecules they interact with, thereby resulting in increased binding affinity. The pharmacokinetic properties of drugs bearing quinoxaline cores have shown them to be relatively easy to administer either as intramuscular solutions, oral capsules or rectal suppositories. This work deals with recent advances in the synthesis and pharmacological diversities of quinoxaline motifs which might pave ways for novel drugs development.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Echinomycin; In vitro; Mycobacterium tuberculosis; Nitrogen heterocycles; Therapeutics

Mesh:

Substances:

Year:  2014        PMID: 25128670     DOI: 10.1016/j.ejmech.2014.08.034

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  8 in total

1.  Isopropyl quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives induce regulated necrosis-like cell death on Leishmania (Leishmania) mexicana.

Authors:  Karla Fabiola Chacón-Vargas; Sergio Andrade-Ochoa; Benjamín Nogueda-Torres; Dulce Carolina Juárez-Ramírez; Edgar E Lara-Ramírez; Ricardo Mondragón-Flores; Antonio Monge; Gildardo Rivera; Luvia Enid Sánchez-Torres
Journal:  Parasitol Res       Date:  2017-11-20       Impact factor: 2.289

2.  Anti-Mycobacterium tuberculosis Activity of Esters of Quinoxaline 1,4-Di-N-Oxide.

Authors:  Isidro Palos; Julieta Luna-Herrera; Edgar E Lara-Ramírez; Alejandra Loera-Piedra; Emanuel Fernández-Ramírez; Ma Guadalupe Aguilera-Arreola; Alma D Paz-González; Antonio Monge; Baojie Wan; Scott Franzblau; Gildardo Rivera
Journal:  Molecules       Date:  2018-06-15       Impact factor: 4.411

3.  Sequential Synthesis, Olfactory Properties, and Biological Activity of Quinoxaline Derivatives.

Authors:  Mia Imanishi; Motohiro Sonoda; Hironari Miyazato; Keiichiro Sugimoto; Mitsugu Akagawa; Shinji Tanimori
Journal:  ACS Omega       Date:  2017-05-08

4.  From Quinoxaline, Pyrido[2,3-b]pyrazine and Pyrido[3,4-b]pyrazine to Pyrazino-Fused Carbazoles and Carbolines.

Authors:  Frédéric Lassagne; Timothy Langlais; Elsa Caytan; Emmanuelle Limanton; Ludovic Paquin; Manon Boullard; Coline Courtel; Idriss Curbet; Clément Gédéon; Julien Lebreton; Laurent Picot; Valérie Thiéry; Mohamed Souab; Blandine Baratte; Sandrine Ruchaud; Stéphane Bach; Thierry Roisnel; Florence Mongin
Journal:  Molecules       Date:  2018-11-13       Impact factor: 4.411

5.  Iron-catalyzed one-pot synthesis of quinoxalines: transfer hydrogenative condensation of 2-nitroanilines with vicinal diols.

Authors:  Ramachandra Reddy Putta; Simin Chun; Seok Beom Lee; Junhwa Hong; Dong-Chan Oh; Suckchang Hong
Journal:  RSC Adv       Date:  2021-05-20       Impact factor: 3.361

6.  Synthesis, In Vitro Antiproliferative Activity, and In Silico Evaluation of Novel Oxiranyl-Quinoxaline Derivatives.

Authors:  Vincent Montero; Marc Montana; Omar Khoumeri; Florian Correard; Marie-Anne Estève; Patrice Vanelle
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-23

7.  A Convenient Way to Quinoxaline Derivatives through the Reaction of 2-(3-Oxoindolin-2-yl)-2-phenylacetonitriles with Benzene-1,2-diamines.

Authors:  Alexander V Aksenov; Nikolai A Arutiunov; Dmitrii A Aksenov; Artem V Samovolov; Igor A Kurenkov; Nicolai A Aksenov; Elena A Aleksandrova; Daria S Momotova; Michael Rubin
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

8.  A High-Throughput Screening Method for Determining the Optimized Synthesis Conditions of Quinoxaline Derivatives Using Microdroplet Reaction.

Authors:  Yanmei Yang; Junmin Liu; Zhenzhen Chen; Weihua Niu; Ran Li; Le Niu; Peng Yang; Xiaoyan Mu; Bo Tang
Journal:  Front Chem       Date:  2020-09-10       Impact factor: 5.221

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.